Moore Capital Management’s AbbVie ABBV Stock Holding History

Moore Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-50,000	Closed	-$6.74M	–	490
2023 Q2	$6.74M	Buy	+50,000	New	+$7.33M	0.12%	132

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Moore Capital Management's ABBV Position: Q4 2025 in Review

Moore Capital Management sold out of AbbVie (ABBV) in Q4 2025, closing a stake of 60,000 shares — an estimated $13.9M sold.

Moore Capital Management first reported a position in ABBV in Q2 2014 and held it in 10 quarters. The position peaked at $19.2M in Q4 2021. 4,145 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

Moore Capital Management reported no remaining AbbVie position as of Q4 2025 after selling out during the quarter.
Moore Capital Management sold 60,000 AbbVie shares in Q4 2025, an estimated $13.9M.
Moore Capital Management first reported a position in AbbVie in Q2 2014 and held it in 10 quarters.
Moore Capital Management's AbbVie position peaked at $19.2M in Q4 2021.
4,145 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Moore Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.